摘要
目的 观察健择 (GEMZAR)联合顺铂 (CDDP)化疗方案在晚期非小细胞肺癌 (NSCLC)疗效及其毒性反应。方法 对 2 0 0 1- 0 5～ 2 0 0 3- 0 6山东省肿瘤医院对 30例晚期NSCLC应用GP联合方案进行化疗。用法 :GEMZAR 10 0 0mg/m2 ,第 1、8天 ;CDDP 2 5mg/m2 ,第 1～ 3天 ,每 2 1d为 1周期 ,至少 2周期。结果 在 30例中CR0例 ,PR 11例 ,RR为 36 7%。在初治的 13例中 6例达PR ,RR为 4 6 %。在 17例复治病人中 ,5例达PR ,RR为2 9%。毒性反应主要为白细胞减少和血小板的降低。结论 健择联合顺铂化疗方案在治疗晚期NSCLC中具有较好疗效及毒性反应低 ,对于老年患者是可以耐受的 ,可作为一、二线用药治疗方案。
Objective To Observe the effects of combination regimen of gemcitabine and cisplatin in treating advanced non-small cell lung cancer (NSCLC).Methods 30 patients with advanced NSCLC were treated with GP(GEMZAR 1000mg/m2 d1,8;CDDP 25mg/m2 d1～3 ).The course was repeated every 3 weeks for at least 2 cycles.Results The overall response rate was 36.7%(11/30),whereas 13 patients had stable disease and 6 patients showed progressive disease.The response rate was 46% in untreated patients and 29% was obtained in treated ones.Significant difference was observed between the two groups (P<0.05).The major side effects were leukopenia and thrombocytopenia.Conclusion Combination regimen of gemcitabine and cisplatin is feasible,efficacious and justified in patients with advanced or metastatic NSCLC.This regimen is mild and tolerable. It can be given as our first and second line regimen for treating advanced NSCLC.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2005年第1期57-58,共2页
Chinese Journal of Practical Internal Medicine
